What was a commonly known secret finally became official Wednesday when the Utah Hockey Club unveiled its new nickname, the Mammoth, and its logo. Last week, the Utah Mammoth name was shown on the ...

Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the Federal Reserve and new trade developments. The S&P 500 rose by 0.43% ...

Microsoft announced a pair of ultraportable Surface devices yesterday, both of which differ significantly from their predecessors. There's the creatively named Surface Laptop 13-inch, which is ...

Based on strong response to our acquisition of all rights to the proposed biosimilar to Cimzia and to the broadening of our development pipeline, we are increasing full year guidance, to $600-$700 ...

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to take a look at where Alvotech (NASDAQ:ALVO) stands against the other stocks ...

Based on strong response to our acquisition of all rights to the proposed biosimilar to Cimzia and to the broadening of our development pipeline, we are increasing full year guidance, to $600-$700 ...

Raised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial ...

If you receive an email about your Social Security statement, proceed with caution: According to a new report from Malwarebytes Labs, hackers are impersonating the Social Security Administration ...

Royalty Pharma reports Q1 2025 financials with 17% portfolio receipts growth, raising 2025 guidance to $2,975-$3,125 million. Royalty Pharma plc announced its financial results for the first ...

Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12% Net cash provided by operating activities of $596 million Raised full year 2025 guidance: Portfolio Receipts ...